1[1]Kremer JM.Rational use of new and existing disease-modifying agents in rheumatoid arthritis.Ann Intern Med,2001,134(8):695-706. 被引量：1
2[2]Miceli-Richard C,Dougados M.Leflunomide for the treatment of rheumatoid arthritis.Expert Opin Pharmacother,2003,4(6):987-997. 被引量：1
3[3]Elkayam O,Yaron I,Shirazi I,et al.Active leflunomide metabolite inhibits interleukin 1beta,tumour necrosis factor alpha,nitric oxide,and metalloproteinase-3 production in activated human synovial tissue cultures.Ann Rheum Dis,2003,62(5):440-443. 被引量：1
4[4]Combe B,Eliaou JF,Daures JP,et al.Prognostic factors in rheumatoid arthritis.Comparative study of two subsets of patients according to severity of articular damage.Br J Rheumatol,1995,34(6):529-534. 被引量：1
5[5]Smolen JS,Kalden JR,Scott DL.Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis:a double-blind,randomized,multicentre trial.Lancet,1999,23(1):259-266. 被引量：1
6[6]Smolen JS.Efficacy and safety of the new DMARD leflunomide:comparison to placebo and sulfasalazine in active rheumatoid arthritis.Scand J Rheumatol Suppl,1999,112(1):15-21. 被引量：1
7[7]Osiri M,Shea B,Robinson V,et al.Leflunomide for treatment of rheumatoid arthritis:a systematic review and metaanalysis.J Rheumatol,2003,30(6):1182-1190. 被引量：1
